Demographics, clinical, pathological and CSF data
| FTLD-Tau | FTLD-TDP | AD | Control | P values* | |
| n | 24 | 25 | 97 | 77 | |
| Age at CSF collection (years) | 66.9 (11.3) | 66.4 (8.7) | 71 (10.6) | 68.2 (9) | 0.06 |
| Female, n (%) | 6 (25) | 13 (52) | 45 (46) | 50 (65) | 0.004 |
| Education (years) | 15.6 (3.5) | 15.1 (2.7) | 14.8 (3.1) | 16.2 (3.2) | 0.05 |
| Age at death (years) | 71.4 (12.6) | 70 (9.5) | 76.6 (10.6) | NA | 0.008 |
| Participants with no AD pathology (NIA-AA stage ≤B1), n (%) | 20 (83) | 18 (72) | 0 | NA | 0.003 |
| Time interval, onset–CSF (years) | 3.8 (2.7) | 3.7 (2.7) | 4.3 (2.6) | NA | 0.521 |
| Time interval, CSF–death (years) | 4.5 (3.6) | 3.6 (3) | 5.6 (3.6) | NA | 0.029 |
| Total disease duration, onset–death (years) | 8.5 (4.6) | 7.2 (3.3) | 9.8 (4.1) | NA | 0.013 |
| sAPPβ (ng/mL) | 477.5 (120) | 544.9 (239.4) | 717.1 (441.6) | 848.4 (381.9) | <0.001 |
| YKL-40 (ng/mL) | 299.8 (69.1) | 265.6 (48.5) | 268.2 (77.2) | 210.3 (55.1) | <0.001 |
| sAPPβ:YKL-40 ratio | 1.67 (0.56) | 2.07 (0.78) | 2.77 (1.5) | 4.19 (1.89) | <0.001 |
Unless otherwise specified, results are expressed as mean (SD).
*P values were obtained by comparing the groups of FTLD-Tau, FTLD-TDP, AD and control. Tukey’s honest significant differences post-hoc comparisons are detailed in figure 2.
AD, Alzheimer’s disease; CSF, cerebrospinal fluid; FTLD, frontotemporal lobar degeneration; NA, not applicable; NIA-AA, National Institute on Aging-Alzheimer’s Association; sAPPβ, soluble β fragment of amyloid precursor protein.